Fate Therapeutics, Inc. (FATE)

Fate Therapeutics topped expectations on both EPS and revenue in the second fiscal quarter of 2026, reported August 13, 2026, with revenue rising 9.2% to roughly $2.1 million (up from $1.9 million a year ago) as the clinical-stage company continued to be driven by its NK- and T-cell immuno-oncology pipeline. Revenue of $2.1 million topped the $1.9 million estimate, +7%, while EPS of -$0.250 topped the -$0.254 estimate by $0.004 and improved 13.8% from -$0.290 a year ago. With gross profit of roughly $2.1 million, operating income was -$31.1 million, and net income came in at -$30.2 million, a 11.5% improvement from -$34.1 million a year ago. Consensus for the next period calls for EPS of -$0.270 on revenue of $1.2 million.